Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03206177 · ClinicalTrials.gov registry record · Phase 1
Paclitaxel/Carboplatin + Galunisertib for Patients With Carcinosarcoma of the Uterus or Ovary
A Phase 1 study, sponsored by University of Oklahoma.
- Completed
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
NCT03206177 is a Phase 1 study that has completed, run by University of Oklahoma. The registered enrollment target is 26 participants.
The verdict
NCT03206177, a Phase 1 study, has completed, sponsored by University of Oklahoma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
Study Summary
This is a Phase 1 B feasibility trial with Galunsertib, a TGFβ inhibitor, in combination with carboplatin/paclitaxel in patients with newly diagnosed, persistent or recurrent carcinosarcoma of the uterus or ovary. The objective of the study is to determine whether this drug combination is safe for this patient population and to see if it is effective in shrinking cancers, keeping them from growing or helping patients live longer.
Interventions
- DRUG Carboplatin
- DRUG Paclitaxel
- DRUG Galunisertib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2017-08-23 |
| Est. Completion | 2024-02-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03206177
The ClinicalTrials.gov registry entry for NCT03206177 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Oklahoma, which has 358 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Carboplatin is the first listed.
NCT03206177 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03206177 about?
NCT03206177 is a clinical study titled "Paclitaxel/Carboplatin + Galunisertib for Patients With Carcinosarcoma of the Uterus or Ovary". This is a Phase 1 B feasibility trial with Galunsertib, a TGFβ inhibitor, in combination with carboplatin/paclitaxel in patients with newly diagnosed, persistent or recurrent carcinosarcoma of the uterus or ovary. The objective of the study is to determine whether this drug combination is safe for t...
What is the current status of trial NCT03206177?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2017-08-23. Estimated completion is 2024-02-13.
What interventions are being tested in trial NCT03206177?
The interventions under investigation include: Carboplatin (DRUG), Paclitaxel (DRUG), Galunisertib (DRUG).
Who is sponsoring clinical trial NCT03206177?
This trial is sponsored by University of Oklahoma, which has 358 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.